JPRN-jRCT2080220563
Unknown
Phase 3
Randomized, Placebo-controlled, Double-blind, Parallel-group, Confirmatory Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia <Phase III Study>
ConditionsSchizophrenia
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Schizophrenia
- Sponsor
- Sumitomo Dainippon Pharma Co., Ltd.
- Enrollment
- 460
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Patient meets DSM\-IV criteria for schizophrenia.
- •\- Patient is 18 or older but younger than 75 years of age on the day of signing informed consent.
- •\- Patient understands the objectives, nature, and other aspects of the study and voluntarily agrees to participate in the study by providing written informed consent.
Exclusion Criteria
- •\- Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus.
- •\- Patient has Parkinson's disease.
- •\- Patient has a history or complication of malignancy.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 - 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple SclerosisMultiple sclerosisMedDRA version: 14.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2006-002633-20-ITGlaxoSmithKline Research & Development Ltd350
Active, not recruiting
Not Applicable
Subcutaneous Ofatumumab in Relapsing Remitting Multiple Sclerosis.Relapsing-Remitting Multiple Sclerosis (RRMS).MedDRA version: 14.1Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2011-002333-19-ITGLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.196
Active, not recruiting
Not Applicable
Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple SclerosisEUCTR2006-002633-20-NLGlaxoSmithKline Research & Development Ltd350
Active, not recruiting
Not Applicable
Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple SclerosisRelapsing-Remitting Multiple SclerosisMedDRA version: 8.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2006-002633-20-FIGlaxoSmithKline Research & Development Ltd350
Active, not recruiting
Phase 1
Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple SclerosisRelapsing-Remitting Multiple SclerosisMedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disordersEUCTR2006-002633-20-GBGlaxoSmithKline Research & Development Ltd